论文部分内容阅读
据报道血清可溶性IL-2受体(sIL-2R)水平增高可见于某些血液系统肿瘤、获得性免疫缺陷器官移植及肉芽肿性疾病。sIL-2R 的生物学作用目前尚不清楚,作者对43例肺癌病人进行血清sIL-2R 检测,旨在探讨sIL-2R与肺癌分期及分型的关系。男性33例,女性10例,年龄63±10岁。小细胞肺癌9例,非小细胞肺癌34例。组织学类型包括鳞癌、腺癌、小细胞癌及未能分类癌。检测前未接受任何治疗,合并有感染者除外。依照TNM 分类,26例患者可分期。血清sIL-2R 采用美国商品化IL-2R 检测药盒测定,以41名年龄、性别与病例组相接近的健康者作为对照。
Serum soluble IL-2 receptor (sIL-2R) levels have been reported to be elevated in certain hematologic malignancies, acquired immunodeficient organ transplants, and granulomatous diseases. The biological role of sIL-2R is still unclear. The authors tested serum sIL-2R in 43 patients with lung cancer to investigate the relationship between sIL-2R and lung cancer staging and classification. There were 33 males and 10 females, aged 63±10 years old. There were 9 cases of small cell lung cancer and 34 cases of non-small cell lung cancer. Histological types include squamous cell carcinomas, adenocarcinomas, small cell carcinomas, and undifferentiated carcinomas. There was no treatment before the test, except for those with complications. According to the TNM classification, 26 patients can be staged. Serum sIL-2R was measured using a commercially available IL-2R test kit, and 41 healthy persons whose age and sex were similar to the case group were used as controls.